<SEC-DOCUMENT>0000929638-25-000810.txt : 20250214
<SEC-HEADER>0000929638-25-000810.hdr.sgml : 20250214
<ACCEPTANCE-DATETIME>20250214171329
ACCESSION NUMBER:		0000929638-25-000810
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250214
DATE AS OF CHANGE:		20250214

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABVC BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-84759
		FILM NUMBER:		25630857

	BUSINESS ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-668-0881

	MAIL ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	American BriVision (Holding) Corp
		DATE OF NAME CHANGE:	20160111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lind Global Fund II LP
		CENTRAL INDEX KEY:			0001871665
		ORGANIZATION NAME:           	
		IRS NUMBER:				863914253
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		444 MADISON AVENUE
		STREET 2:		41ST FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		646-701-7428

	MAIL ADDRESS:	
		STREET 1:		444 MADISON AVENUE
		STREET 2:		41ST FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0000929638-23-002183</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001871665</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>3</amendmentNo>
<securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001173313</issuerCik>
<issuerName>ABVC BIOPHARMA, INC.</issuerName>
<issuerCusip>00091F304</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>44370 OLD WARM SPRINGS BLVD.</com:street1>
<com:city>FREMONT</com:city>
<com:stateOrCountry>CA</com:stateOrCountry>
<com:zipCode>94538</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Lind Global Fund II LP</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>1325000</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>1325000</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1325000</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>9.9</classPercent>
<typeOfReportingPerson>PN</typeOfReportingPerson>
<comments>(1) The reporting person's ownership consists of (i) 94,994 shares of common stock, (ii) 29,167 warrants to purchase shares of common stock (the "A Warrants"), (iii) 1,000,000 warrants to purchase shares of common stock (the "B Warrants", together with the A Warrants, the "Warrants"), and (iv) shares of common stock issuable to the reporting person pursuant to convertible securities entered into between Lind Global Fund II and ABVC BioPharma, Inc. (the "Convertible Securities"); however, due to the exercise limitations of the Warrants and the conversion limitations on the Convertible Securities, the reporting person's beneficial ownership has been limited to 1,325,000 shares in the aggregate.&#13;
&#13;
(2) The Warrants and the Convertible Securities each include a provision limiting the holder's ability to exercise the Warrants or convert the Convertible Securities if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.</comments>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Lind Global Partners II LLC</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>1325000</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>1325000</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1325000</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>9.9</classPercent>
<typeOfReportingPerson>OO</typeOfReportingPerson>
<comments>(1) The reporting person's ownership consists of (i) 94,994 shares of common stock, (ii) 29,167 A Warrants, (iii) 1,000,000 B Warrants, and (iv) shares of common stock issuable to the reporting person pursuant to the Convertible Securities; however, due to the exercise limitations of the Warrants and the conversion limitations on the Convertible Securities, the reporting person's beneficial ownership has been limited to 1,325,000 shares in the aggregate.&#13;
&#13;
(2) The Warrants and the Convertible Securities each include a provision limiting the holder's ability to exercise the Warrants or convert the Convertible Securities if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.</comments>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>EASTON JEFF</reportingPersonName>
<citizenshipOrOrganization>X1</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>1325000</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>1325000</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1325000</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>9.9</classPercent>
<typeOfReportingPerson>IN</typeOfReportingPerson>
<comments>(1) The reporting person's ownership consists of (i) 94,994 shares of common stock, (ii) 29,167 A Warrants, (iii) 1,000,000 B Warrants, and (iv) shares of common stock issuable to the reporting person pursuant to the Convertible Securities; however, due to the exercise limitations of the Warrants and the conversion limitations on the Convertible Securities, the reporting person's beneficial ownership has been limited to 1,325,000 shares in the aggregate.&#13;
&#13;
(2) The Warrants and the Convertible Securities each include a provision limiting the holder's ability to exercise the Warrants or convert the Convertible Securities if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.</comments>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>ABVC BIOPHARMA, INC.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>44370 OLD WARM SPRINGS BLVD., FREMONT, California, 94538</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"):&#13;
&#13;
   o   Lind Global Fund II LP, a Delaware limited partnership;&#13;
   o   Lind Global Partners II LLC, a Delaware limited liability company; and&#13;
   o   Jeff Easton, an individual and a citizen of the United States of America.&#13;
&#13;
Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.&#13;
&#13;
Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>The address of the principal business office for each of the Reporting Persons is:&#13;
&#13;
444 Madison Ave, Floor 41 &#13;
New York, NY 10022</principalBusinessOfficeOrResidenceAddress>
<citizenship>See Row 4 of cover page for each Reporting Person.</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>See Row 9 of cover page for each Reporting Person.</amountBeneficiallyOwned>
<classPercent>See Row 11 of cover page for each Reporting Person.</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>See Row 5 of cover page for each Reporting Person.</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>See Row 6 of cover page for each Reporting Person.</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>See Row 7 of cover page for each Reporting Person.</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>See Row 8 of cover page for each Reporting Person.</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>Y</notApplicableFlag>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
</item10>
</items>
<exhibitInfo>99.1     Joint Filing Application by and among the Reporting Persons</exhibitInfo>
<signatureInformation>
<reportingPersonName>Lind Global Fund II LP</reportingPersonName>
<signatureDetails>
<signature>By: Lind Global Partners II LLC, its General Partner, By:  /s/ Jeff Easton</signature>
<title>Jeff Easton, Managing Member</title>
<date>02/14/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>Lind Global Partners II LLC</reportingPersonName>
<signatureDetails>
<signature>/s/ Jeff Easton</signature>
<title>Jeff Easton, Managing Member</title>
<date>02/14/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>EASTON JEFF</reportingPersonName>
<signatureDetails>
<signature>/s/ Jeff Easton</signature>
<title>Jeff Easton</title>
<date>02/14/2025</date>
</signatureDetails>
</signatureInformation>
</formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>JOINT FILING APPLICATION BY AND AMONG THE REPORTING PERSONS
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Morgan Lewis
         Document created using Broadridge PROfile 25.1.1.5279
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-weight: bold;">Exhibit 99.1</div>
  </div>
  <div><br>
  </div>
  <div>
    <div style="text-align: center; font-weight: bold;">JOINT FILING APPLICATION</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of ABVC BioPharma, Inc. shall be filed on behalf of each
      of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">February 14, 2025</div>
    <div>&#160;</div>
    <table style="border-collapse: collapse; width: 200pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z716d2225c32e4c01a023602ca7efc199" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="3" style="vertical-align: top;">
            <div style="font-weight: bold;">LIND GLOBAL FUND II LP</div>
          </td>
        </tr>
        <tr>
          <td colspan="3" style="vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45pt; vertical-align: top;">
            <div>By:</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div>Lind Global Partners II LLC</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45pt; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">
            <div>its General Partner</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45pt; vertical-align: middle;">&#160;</td>
          <td colspan="2" style="vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45pt; vertical-align: top;">
            <div>By:</div>
          </td>
          <td colspan="2" style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0);">
            <div>/s/ Jeff Easton</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45pt; vertical-align: top;">
            <div>Name:</div>
          </td>
          <td colspan="2" style="vertical-align: top; border-top: 1px solid rgb(0, 0, 0);">
            <div>Jeff Easton</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45pt; vertical-align: top;">
            <div>Title:</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div>Managing Member</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45pt; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="vertical-align: top;">
            <div style="font-weight: bold;">LIND GLOBAL PARTNERS II LLC</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45pt; vertical-align: middle;">&#160;</td>
          <td colspan="2" style="vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45pt; vertical-align: top;">
            <div>By:</div>
          </td>
          <td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top;">
            <div>/s/ Jeff Easton</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45pt; vertical-align: top;">
            <div>Name:</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div>Jeff Easton</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45pt; vertical-align: top;">
            <div>Title:</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div>Managing Member</div>
          </td>
        </tr>
        <tr>
          <td colspan="3" style="vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="vertical-align: middle;">
            <div style="font-weight: bold;">JEFF EASTON</div>
          </td>
        </tr>
        <tr>
          <td colspan="3" style="vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45pt; vertical-align: top;">
            <div>By:</div>
          </td>
          <td style="width: 5pt; vertical-align: bottom;">
            <div>&#160;</div>
          </td>
          <td style="width: 150pt; vertical-align: top; border-bottom: 1px solid;">
            <div>
              <div>/s/ Jeff Easton</div>
            </div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
